Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APLT Stock Forecast 2026-2027
$0.10
Current Price
$14.86M
Market Cap
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to APLT Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
APLT Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-75.0%
1 Year Change
0.0%
Year-to-Date Change
-93.1%
From 52W High of $1.50
+14.4%
From 52W Low of $0.09
📊 TOP ANALYST CALLS
Did APLT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Applied Therapeutics is one of their latest high-conviction picks.
Latest APLT Stock Price Targets & Analyst Predictions
APLT has shown a year-to-date change of 0.0% and a 1-year change of -75.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for APLT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLT Analyst Ratings
0
Buy
3
Hold
0
Sell
APLT Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.10
Latest APLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2025 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $1.00 |
| May 14, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Reiterates | $1.50 |
| Dec 23, 2024 | William Blair | Sami Corwin | Market Perform | Downgrade | $N/A |
| Dec 20, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $1.50 |
| Dec 2, 2024 | UBS | Esther Rajavelu | Neutral | Downgrade | $2.00 |
| Nov 29, 2024 | Baird | Brian Skorney | Outperform | Maintains | $5.00 |
| Nov 29, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $4.00 |
| Nov 29, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Nov 27, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $13.00 |
| Sep 19, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Maintains | $14.00 |
| Sep 19, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $11.00 |
| Aug 27, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Jul 31, 2024 | William Blair | Tim Lugo | Outperform | Initiates | $N/A |
| Jul 17, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $12.00 |
| Apr 11, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $12.00 |
| Mar 26, 2024 | RBC Capital | Brian Abrahams | Outperform | Initiates | $12.00 |
| Mar 15, 2024 | UBS | Esther Rajavelu | Buy | Maintains | $13.00 |
| Mar 6, 2024 | UBS | Esther Rajavelu | Buy | Maintains | $12.00 |
| Feb 22, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Initiates | $12.00 |
| Feb 16, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $7.00 |
Applied Therapeutics Inc (APLT) Competitors
The following stocks are similar to Applied Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
APLT
Applied Therapeutics
mkt cap
14.86M
Applied Therapeutics Inc (APLT) Financial Data
Applied Therapeutics Inc has a market capitalization of $14.86M with a P/E ratio of -0.1x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +719.7% quarter-over-quarter, while maintaining an operating margin of -1,796.7% and return on equity of -680.5%.
Valuation Metrics
Market Cap
$14.86M
Enterprise Value
$5.42M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
14.9x
Growth & Margins
Revenue Growth (YoY)
+719.7%
Gross Margin
N/A
Operating Margin
-1,796.7%
Net Margin
0.0%
EPS Growth
+719.7%
Financial Health
Cash/Price Ratio
+80.6%
Current Ratio
1.0x
Debt/Equity
-4.5x
ROE
-680.5%
ROA
-88.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Applied Therapeutics Inc (APLT) Business Model
About Applied Therapeutics Inc
What They Do
Develops novel treatments for unmet medical needs.
Business Model
Applied Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies for rare metabolic and inflammatory diseases. The company generates revenue primarily through the advancement of its drug candidates, which are designed to fill significant therapeutic gaps in the market, particularly for conditions like Galactosemia.
Additional Information
Based in New York City, Applied Therapeutics is positioned in the biotechnology sector, emphasizing research and development in areas with high unmet medical needs. Their commitment to advancing treatments for orphan diseases enhances the potential for better health outcomes and contributes to the overall growth of the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Les D. Funtleyder
Country
United States
IPO Year
2019
Website
www.appliedtherapeutics.comApplied Therapeutics Inc (APLT) Latest News & Analysis
Latest News
Quick Summary
Cycle Group Holdings Limited has acquired NASDAQ-listed Applied Therapeutics, Inc., a biopharmaceutical company focused on CNS rare metabolic diseases, enhancing Cycle's portfolio.
Why It Matters
Cycle Group's acquisition of Applied Therapeutics enhances its portfolio with a promising drug candidate, potentially increasing future revenue and market positioning in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
4 months ago
Quick Summary
Applied Therapeutics announced a pending tender offer by AT2B, Inc., a subsidiary of Cycle Group Holdings. Further details were provided in a letter to stockholders.
Why It Matters
The pending tender offer by AT2B, Inc. for Applied Therapeutics may indicate a potential acquisition, impacting stock value and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cycle Group Holdings has extended its tender offer for Applied Therapeutics shares at $0.088 per share. The new expiration date has not been specified in the announcement.
Why It Matters
Cycle Group's extension of the tender offer for Applied Therapeutics indicates a strategic move that could impact stock value and investor sentiment, highlighting potential acquisition dynamics.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Applied Therapeutics (APLT) shows a hammer chart pattern, suggesting recent support after a decline. Upward revisions in earnings estimates may indicate a potential trend reversal.
Why It Matters
The hammer chart pattern suggests potential support for Applied Therapeutics, while rising earnings estimates indicate a possible trend reversal, signaling a favorable investment opportunity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Halper Sadeh LLC is investigating the fairness of Applied Therapeutics' sale to Cycle Group Holdings for $0.088/share plus contingent value rights, advising shareholders on their legal options.
Why It Matters
The investigation into the sale of Applied Therapeutics may indicate potential undervaluation and legal risks, affecting shareholder sentiment and stock price volatility.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Applied Therapeutics' lead drug candidate, govorestat, is a new Aldose Reductase Inhibitor targeting rare central nervous system metabolic diseases.
Why It Matters
Govorestat's development could position Applied Therapeutics as a key player in treating rare CNS diseases, potentially boosting its market value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APLT Stock
What is Applied Therapeutics Inc's (APLT) stock forecast for 2026?
Analyst forecasts for Applied Therapeutics Inc (APLT) are not currently available. The stock is trading at $0.10.
Is APLT stock a good investment in 2026?
According to current analyst ratings, APLT has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLT stock?
Price predictions from Wall Street analysts for APLT are not currently available. The stock is trading at $0.10.
What is Applied Therapeutics Inc's business model?
Applied Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies for rare metabolic and inflammatory diseases. The company generates revenue primarily through the advancement of its drug candidates, which are designed to fill significant therapeutic gaps in the market, particularly for conditions like Galactosemia.
What is the highest forecasted price for APLT Applied Therapeutics Inc?
Price targets from Wall Street analysts for APLT are not currently available. The stock is trading at $0.10.
What is the lowest forecasted price for APLT Applied Therapeutics Inc?
Price targets from Wall Street analysts for APLT are not currently available. The stock is trading at $0.10.
What is the overall APLT consensus from analysts for Applied Therapeutics Inc?
The overall analyst consensus for APLT is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell.
How accurate are APLT stock price projections?
Stock price projections, including those for Applied Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 8:37 PM UTC